DISEASE & TREATMENT SETTING

Acute Lymphoblastic Leukemia

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Untreated ALL

Broader topic: Acute Lymphoblastic Leukemia

Source population: Not part of this definition
Disease extent: Not part of this definition
Treatment line: Not part of this definition
Stage: Not part of this definition
Resectability: Not part of this definition

Biomarkers, prior therapy and derivation

molecular

prior therapy

class
no prior therapy
status
stated

derivation status

source-attested

derivation note

Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.

source wording

Treatment of Untreated ALL

Study evidence for this setting

Find a linked studyHow it was found

0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

Indication-specific source history

Dated source events, not confirmation of current approval for every use of a drug.

2005-10-28 · Arranon (nelarabine) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-d3d8bdae0842b433
event date: 2005-10-28
event kind: accelerated-approval
drug or regimen: Arranon (nelarabine)
source indication text: Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-f58aef392b7fc74222f1
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2012-12-14 · Iclusig (ponatinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-108760cbb44327a3
event date: 2012-12-14
event kind: accelerated-approval
drug or regimen: Iclusig (ponatinib)
source indication text: Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-207b1271c5e76362e54d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2014-12-03 · Blincyto (blinatumomab) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-e67e34379a36dfdb
event date: 2014-12-03
event kind: accelerated-approval
drug or regimen: Blincyto (blinatumomab)
source indication text: Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-82907dc69f86ffd38c79
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2016-11-28 · Iclusig (ponatinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-89a66bf821990fc4
event date: 2016-11-28
event kind: traditional-approval
drug or regimen: Iclusig (ponatinib)
source indication text: Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-207b1271c5e76362e54d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2017-07-11 · Blincyto (blinatumomab) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-bd3e064bf368c79b
event date: 2017-07-11
event kind: traditional-approval
drug or regimen: Blincyto (blinatumomab)
source indication text: Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-82907dc69f86ffd38c79
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2018-03-29 · Blincyto (blinatumomab) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-d54672791d176b57
event date: 2018-03-29
event kind: accelerated-approval
drug or regimen: Blincyto (blinatumomab)
source indication text: Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children 1
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-02f492ec41663fb81dfc
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2019-07-31 · Arranon (nelarabine) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-eff4f805d1d9d834
event date: 2019-07-31
event kind: traditional-approval
drug or regimen: Arranon (nelarabine)
source indication text: Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-f58aef392b7fc74222f1
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2023-06-20 · Blincyto (blinatumomab) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-785ccbcbc3fd8863
event date: 2023-06-20
event kind: traditional-approval
drug or regimen: Blincyto (blinatumomab)
source indication text: Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children 1
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-02f492ec41663fb81dfc
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2024-03-19 · Iclusig (ponatinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia-scoped-baea2be1
event id: fda-6cc8ad68ff376d34
event date: 2024-03-19
event kind: accelerated-approval
drug or regimen: Iclusig (ponatinib)
source indication text: Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
match phrase: acute lymphoblastic leukemia
match status: candidate
status category: ongoing
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-aeff872fb7dd4814dd77
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

Source relationships and population-mapping limitations

bindings
mappings

Download this complete draft source relationship record →

Preserved source evidence · Not medical advice